

01<sup>st</sup> November, 2022

**BSE Limited**

P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Regulation 29 and Regulation 50 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')**

**Unaudited Financial Results (Standalone and Consolidated)  
For the quarter and half year ended 30<sup>th</sup> September, 2022  
Board Meeting on 08<sup>th</sup> November, 2022**

Dear Sir / Madam,

Pursuant to Regulation 29 and 50 of the Listing Regulations, we write to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, 08<sup>th</sup> November, 2022, *inter alia* to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30<sup>th</sup> September, 2022.

In this regard, we write to inform you that the 'Trading Window' for dealing in the securities of the Company has been closed from Wednesday, 19<sup>th</sup> October, 2022 and will remain closed till Thursday, 10<sup>th</sup> November, 2022 (both days inclusive).

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

**Vivek Valsaraj**  
**Whole-Time Director & CFO**

**Piramal Pharma Limited**

CIN: U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

[piramal.com](http://piramal.com)